Company record · updated August 5, 2026
Alto Neuroscience, Inc.: 4 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs January 12, 2024 to January 12, 2024.
4observations
1source filings
4verified rows
2024-01-12most recent as-of date
Source rails for this company: S-1 charter round (4).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2024-01-12 | Series SEED price per share | 2.0822 USD | — | VERIFIED | "Original Issue Price" defined for Series SEED | 000119312524007592 |
| 2024-01-12 | Series C price per share | 4.7131 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312524007592 |
| 2024-01-12 | Series B price per share | 6 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312524007592 |
| 2024-01-12 | Series A price per share | 4.6996 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312524007592 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.